×
Abstract P5-11-04: Therapy-induced priming of natural killer cells predicts patient-specific tumor rejection in multiple breast cancer indications
http://cancerres.aacrjournals.org/content/78/4_Supplement/P5-11-04

Jul 18th, 2018 - Background: Predicting patient-specific clinical response to anticancer therapy is the holy grail of treatment-selection. It is now clear that response or resistance to therapy depends on the heterogeneous tumor microenvironment, which is comprised of malignant cells, normal stroma, soluble ligands, and tumor-immune contexture; attributes that are unique to each individual patient. This is part...

Again, a PARP Inhibitor Has Potential in BRCA+ Breast Cancer
http://www.medscape.com/viewarticle/889875

Dec 10th, 2017 - A second PARP inhibitor shows promise in germline mutation metastatic breast cancer and is generally well tolerated compared with standard chemotherapy.

Adjuvant Zoledronic Acid in Early Breast Cancer: Is 5 Years Better?
http://www.ascopost.com/issues/february-10-2018/adjuvant-zoledronic-acid-in-early-breast-cancer-is-5-years-better/

Feb 9th, 2018 - THE PHASE III SUCCESS A trial, presented at the 2017 San Antonio Breast Cancer Symposium, found no benefit for extending the use of intravenous zoledronic acid from 2 years to 5 years.

Abstract P4-08-05: Impact of common polymorphisms of CYP19A1 and UGT2B17 gene deletion on early endocrine-responsive postmenopausal breast cancer
http://cancerres.aacrjournals.org/content/78/4_Supplement/P4-08-05

Jul 22nd, 2018 - Background Polymorphisms of genes involved in estrogen production have been linked to breast cancer risk, prognosis and treatment response. Polymorphisms of the aromatase gene CYP19A1 influence its activity. The UGT2B17 catalyzes glucuronic acid transfer to a variety of substrates, including steroids and drugs like the aromatase inhibitor exemestane. We investigated the impact of two variants o...

Axillary Node Management for Breast Cancer: Is Less More?
https://www.cancertherapyadvisor.com/breast-cancer/breast-cancer-axillary-node-management-treatment/article/713742/

Dec 11th, 2017 - Ongoing clinical trials should clarify optimal axilla management and treatment de-escalation options for patients with normal axillary ultrasound findings.

Breast Pain Uncommon Symptom of Breast Cancer
http://www.medscape.com/viewarticle/890247

Dec 17th, 2017 - Breast pain is not often a symptom of breast cancer regardless of age, and mostly women need to be reassured that breast pain is both common and benign.

Abstract P1-06-12: Optimizing the use of oncotype Dx in early breast cancer
http://cancerres.aacrjournals.org/content/78/4_Supplement/P1-06-12

Jul 30th, 2018 - Background: Oncotype Dx (ODX) prognosticates the risk of recurrence and predicts the benefit of adjuvant chemotherapy in estrogen-receptor-positive breast cancer (BC). However, its cost makes it prohibitive for many health care systems. Our objective was to develop a model that uses routine clinical and pathological parameters to identify ODX high risk patients which require adjuvant chemothera...

CDK 4/6 Inhibitors May Be Effective but More Toxic in Older Women
http://www.ascopost.com/issues/february-10-2018/cdk-46-inhibitors-may-be-effective-but-more-toxic-in-older-women/

Feb 9th, 2018 - OLDER WOMEN with breast cancer derive benefit from treatment with cyclin-dependent kinase (CDK) 4/6 inhibitors as part of initial endocrine-based therapy for hormone receptor–positive, HER2-negative, metastatic breast cancer, according to a retrospective pooled subgroup analysis of women aged 70 or older enrolled in registration trials of these agents.

CDK4/6 Improved PFS in Older Women with HR+ Metastatic Breast Cancer
https://www.onclive.com/conference-coverage/sabcs-2017/cdk46-improved-pfs-in-older-women-with-hr-metastatic-breast-cancer-

Dec 7th, 2017 - Older women with HR–positive breast cancer treated with a CDK4/6 inhibitor may derive a progression-free survival  benefit similar to that seen in their younger counterparts

Abstract P1-06-07: Mayo clinic TNBC outcome calculator: A clinical calculator to predict disease relapse and survival in women with triple-negative breast cancer
http://cancerres.aacrjournals.org/content/78/4_Supplement/P1-06-07

Aug 3rd, 2018 - Purpose: Triple negative breast cancer (TNBC) is an aggressive breast cancer subtype with substantial risks of disease recurrence. While cytotoxic chemotherapy is commonly administered and reduces recurrence, disease outcomes vary considerably and few prognostic tools are available for risk stratification for TNBC patients. We constructed and validated clinical calculators for invasive-disease ...

Abstract P1-06-10: Correlative analysis of breast cancer index (BCI) restratification of 21-gene recurrence score (RS) in patients with hormone receptor-positive (HR+), node-negative breast cancer
http://cancerres.aacrjournals.org/content/78/4_Supplement/P1-06-10

Aug 4th, 2018 - Background: In a cross-stratification analysis performed within the TransATAC cohort, Breast Cancer Index (BCI) and 21-gene Recurrence Score (RS) had a concordance of 58.2% (Sestak et al., Clin Cancer Res, 2016). Restratification by BCI of the low and intermediate RS risk groups led to subgroups with significantly different rates (P < 0.001 and P = 0.003, respectively); in contrast, restratifie...

Abstract P3-08-08: Prognostic associations of plasma hepcidin in early breast cancer (BC)
http://cancerres.aacrjournals.org/content/78/4_Supplement/P3-08-08

Aug 14th, 2018 - Background: Intra-tumor RNA expression of hepcidin has been linked to adverse metastasis-free survival in women with early BC, but the prognostic implications of this inflammatory marker and iron-regulating peptide are unknown. Methods: Using an ELISA assay, we measured plasma hepcidin in the banked blood of 518 women who were recruited from 1989-1996 for a prospective cohort study regarding di...

Abstract P3-08-13: Serum thymidine kinase activity is an independent prognostic factor for progression-free and overall survival in women with metastatic breast cancer
http://cancerres.aacrjournals.org/content/78/4_Supplement/P3-08-13

Aug 20th, 2018 - Introduction: Although prognosis and treatment of metastatic breast cancer (MBC) have improved over the last years, there is still an unmet clinical need for more precise prognostic and treatment monitoring tools. Liquid-based markers are preferred since they reflect real-time tumor progression and are not dependent on repeated invasive tissue biopsies. Thymidine kinase 1 (TK1) is an enzyme inv...

Dosing Modifications Shown to Improve Outcomes In Breast Cancer
https://www.targetedonc.com/conference/2017-sabcs/dosing-modifications-shown-to-improve-outcomes-in-breast-cancer

Dec 5th, 2017 - Early-stage breast cancer recurrence and mortality was reduced by shortening the intervals between chemotherapy cycles or administering the drugs sequentially compared with standard dosing techniques, according to meta-analysis results presented at the 2017 San Antonio Breast Cancer Symposium.

Enzalutamide plus exemestane improves PFS in HR+ breast cancer subset
https://www.mdedge.com/oncologypractice/article/155272/breast-cancer/enzalutamide-plus-exemestane-improves-pfs-hr-breast

Jan 1st, 2018 - Enzalutamide added to exemestane improved progression-free survival (PFS) in patients with hormone receptor (HR)-positive advanced breast cancer, investigators reported

ERBB2 expression predicts pCR in HER2+ breast cancer
https://www.mdedge.com/oncologypractice/article/155137/breast-cancer/erbb2-expression-predicts-pcr-her2-breast-cancer

Dec 25th, 2017 - Among patients receiving trastuzumab plus lapatinib neoadjuvant therapy for HER2-positive early breast cancer, amplification of ERBB2 was predictive of a pathologic complete response (pCR), according to findings presented at the San Antonio Breast Cancer Symposium.

Abstract P5-18-01: Extended continuous vs intermittent adjuvant letrozole in postmenopausal women with lymph node-positive, early breast cancer (IBCSG 37-05/BIG 1-07 SOLE): Impact on patient-report...
http://cancerres.aacrjournals.org/content/78/4_Supplement/P5-18-01

Aug 23rd, 2018 - Background: SOLE efficacy results presented at ASCO 2017 showed that extended intermittent vs continuous letrozole for 5 years did not improve disease-free survival in postmenopausal women who had received 4-6 years of adjuvant endocrine therapy for hormone-receptor positive (HR+), lymph-node positive breast cancer. Previous studies showed that the burden by symptoms related to endocrine therap...

Exemestane plus enzalutamide extends PFS in some women with breast cancer
https://www.healio.com/hematology-oncology/breast-cancer/news/online/%7B99e9af8c-7703-431e-ab0d-71b296bb9b5b%7D/exemestane-plus-enzalutamide-extends-pfs-in-some-women-with-breast-cancer

Dec 7th, 2017 - The addition of enzalutamide to exemestane significantly prolonged PFS and appeared well tolerated among patients with hormone receptor-positive metastatic breast cancer who had not received prior endocrine therapy and who expressed an androgen receptor gene signature, according to results of a placebo-controlled randomized phase 2 trial presented at the San Antonio Breast Cancer Symposium.

Extended Endocrine Therapy in Postmenopausal Women With Breast Cancer: 2 Years as Effective as 5 Years
http://www.ascopost.com/issues/december-25-2017/extended-endocrine-therapy-in-postmenopausal-women-with-breast-cancer-2-years-as-effective-as-5-years/

Dec 24th, 2017 - An additional 5 years of aromatase inhibitor therapy after 5 years of adjuvant endocrine therapy failed to improve disease-free survival compared with an additional 2 years of aromatase inhibitor therapy in postmenopausal women with hormone receptor–positive breast cancer, according to the results of the large Austrian Breast and Colorectal Cancer Study Group (ABCSG)-16 trial presented at the 2...

Abstract P5-18-04: Bridging gaps in breast cancer care: A pilot forum for mental health professionals
http://cancerres.aacrjournals.org/content/78/4_Supplement/P5-18-04

Aug 25th, 2018 - Introduction: Supporting the emotional needs of women diagnosed with breast cancer is a recognized priority for cancer clinicians and a core component of high quality care and survivorship programs. We hypothesized that mental health professionals would benefit from an educational program directed to enhance their practical knowledge of breast cancer. Methods: We designed an innovative educatio...

Fulvestrant + Anastrozole Improves Long-Term PFS and OS vs Anastrozole Alone in Women With Postmenopausal Metastatic Breast Cancer
https://www.practiceupdate.com/content/sabcs-2017nbspfulvestrant-anastrozole-improves-long-term-pfs-and-os-vs-anastrozole-alone-in-women-with-postmenopausal-metastatic-breast-cancer/61146/62

Dec 7th, 2017 - Fulvestrant + anastrozole has been shown to improve long-term progression-free and overall survival vs anastrozole alone in women with postmenopausal metastatic breast cancer, despite the use of fulvestrant at a lower dose than approved, and despite substantial crossover to fulvestrant after progression with anastrozole alone.

Abstract P6-11-02: Voice of cancer patients: Analysis of patient concerns regarding scalp cooling devices for prevention of chemotherapy induced alopecia
http://cancerres.aacrjournals.org/content/78/4_Supplement/P6-11-02

Aug 27th, 2018 - Adjuvant chemotherapies for breast cancer cause hair loss in majority of patients. Although Chemo Induced Alopecia (CIA) is temporary, is distressing for many patients and about 7% patients treated with docetaxel experience permanent hair loss. Scalp cooling devices (SCDs) have been shown to reduce hair loss in patients receiving chemo. Many patients share their experiences in online forums as ...

Abstract P6-11-06: Efficacy of scalp cooling in preventing chemotherapy-induced alopecia in breast cancer patients: A retrospective, comprehensive review of 330 cases of Brazil
http://cancerres.aacrjournals.org/content/78/4_Supplement/P6-11-06

Aug 28th, 2018 - Background: Chemotherapy-induced alopecia (CIA) is a distressing adverse effect of many chemotherapy (CT) agents. New strategies for prevention of CIA have been studied. Scalp cooling has been reported to prevent CIA. We conducted a retrospective study aimed to assess the efficacy of scalp cooling in preventing CIA among women receiveing chemotherapy for breast cancer. Methods: Was included cli...

Gene-Based Biomarker Identifies Patients With Breast Cancer More Likely to Respond to Enzalutamide
https://www.onclive.com/conference-coverage/sabcs-2017/genebased-biomarker-identifies-patients-with-breast-cancer-more-likely-to-respond-to-enzalutamide

Dec 7th, 2017 - Enzalutamide (Xtandi) added to exemestane improved progression-free survival in patients with hormone receptor-positive advanced breast cancer and no prior endocrine therapy who were positive for a gene signature-based biomarker indicating androgen receptor-signaling.

Lapatinib plus trastuzumab improves outcomes in HER2+ breast cancer
https://www.mdedge.com/oncologypractice/article/155150/breast-cancer/lapatinib-plus-trastuzumab-improves-outcomes-her2

Dec 26th, 2017 - Results from CALGB 40601 conflict with those from two larger trials that failed to find a benefit for dual HER2 blockade in treating HER2+ breast cancer.

High rate of arm morbidity in young breast cancer survivors
https://www.mdedge.com/oncologypractice/article/154705/breast-cancer/high-rate-arm-morbidity-young-breast-cancer-survivors

Dec 17th, 2017 - Undergoing axillary lymph node dissection (ALND) is more likely to result in arm swelling and decreased range of arm motion in young breast cancer patients, as compared with having a sentinel lymph node biopsy (SLNB), according to new findings.

Modest Weight Loss Cuts Postmenopausal Breast Cancer Risk
http://www.medscape.com/viewarticle/889854

Dec 10th, 2017 - Women who lose just 5% of their body weight after the menopause may experience a significant reduction in their risk of developing breast cancer vs women with stable weight, say US researchers.

Abstract P6-11-08: Chemotherapy-induced peripheral neuropathy and quality of life among breast cancer survivors
http://cancerres.aacrjournals.org/content/78/4_Supplement/P6-11-08

Aug 29th, 2018 - Introduction: Breast cancer survivors are at risk for long-term chemotherapy-induced peripheral neuropathy (PN), which has few treatment options and can affect quality of life. We examined 1) the presence and severity of PN and its correlates among 442 metastatic (MBC) and 238 breast cancer (BC) survivors who received chemotherapy, and 2) provider communication, preparation, and confidence in m...

Poor Prognostic Markers Predict for Abemaciclib Benefit in Patients With Breast Cancer
https://www.cancertherapyadvisor.com/breast-cancer/abemaciclib-benefit-breast-cancer-poor-prognostic-markers-risk/article/713426/

Dec 10th, 2017 - This analysis was undertaken to determine whether patient and disease characteristics can predict which patients will benefit from abemaciclib.

Phase III trial data supports current standard 12-month adjuvant trastuzumab for HER2-positive breast cancer
https://ecancer.org/conference/966-sabcs-2017/news/12915-sabcs-2017--phase-iii-trial-data-supports-current-standard-12-month-adjuvant-trastuzumab-for-her2-positive-breast-cancer.php

Dec 6th, 2017 - Disease-free survival (DFS) after nine weeks of adjuvant trastuzumab and standard chemotherapy was not comparable to DFS after 12 months of adjuvant trastuzumab and standard chemotherapy for women with early-stage HER2-positive breast cancer, supporting the current practice of extended trastuzumab treatment, according to data from the phase III Synergism or Long Duration (SOLD) clinical trial, ...

Abstract P6-11-14: Safety and effectiveness of sensor-controlled scalp cooling to prevent alopecia in primary breast cancer patients receiving neoadjuvant or adjuvant epirubicin, taxanes, or both
http://cancerres.aacrjournals.org/content/78/4_Supplement/P6-11-14

Sep 8th, 2018 - Background: Chemotherapy (Ctx)-induced alopecia (CIA), produces a deep psychological distress in many women involved. Sensor-controlled scalp cooling (SCSC) is now approved by the FDA due to both its effectiveness and safety to prevent CIA demonstrated in two randomized trials in patients (pts) with primary breast cancer (PBC). However, SCSC is still infrequently used in many countries due to p...

Ribociclib Doubles Progression-Free Survival in Premenopausal Breast Cancer
http://www.ascopost.com/issues/december-25-2017/ribociclib-doubles-progression-free-survival-in-premenopausal-breast-cancer/

Dec 24th, 2017 - PREMENOPAUSAL WOMEN with hormone receptor–positive, HER2-negative advanced breast cancer benefited substantially from the addition of ribociclib (Kisqali) to first-line endocrine therapy plus medical ovarian suppression, according to results from the MONALEESA-7 study.

Researchers quantify presence of immunotherapy biomarkers in breast cancer
https://www.healio.com/hematology-oncology/breast-cancer/news/online/%7B4ee9505a-d5b1-4da3-b899-d6c77ebc5a22%7D/researchers-quantify-presence-of-immunotherapy-biomarkers-in-breast-cancer

Dec 7th, 2017 - Although a minority of patients with invasive breast cancer expressed microsatellite instability, high tumor mutational load or PD-L1 expression, these biomarkers may elucidate the benefit of immune checkpoint inhibitors for the disease, according to results of a retrospective data analysis presented at the San Antonio Breast Cancer Symposium.

Abstract P5-22-07: Upgrade to high risk lesions, in situ and invasive cancer among women with benign papillary lesions diagnosed on image-guided core needle biopsy (IGCNB)
http://cancerres.aacrjournals.org/content/78/4_Supplement/P5-22-07

Dec 14th, 2018 - Background: Currently there is no consensus regarding the management of benign papillary breast lesions diagnosed on IGCNB. Recommendations vary as to whether all IGCNB papillary lesions require surgical excision or if IGCNB alone is adequate to confirm a benign diagnosis and patients can be followed with imaging. Aims: To estimate percentage of patients with benign papilloma on IGNB who on sur...

Ribociclib Improves PFS by 10.8 Months in HR+/HER2- Premenopausal Breast Cancer
https://www.onclive.com/conference-coverage/sabcs-2017/ribociclib-improves-pfs-by-108-months-in-hrher2-premenopausal-breast-cancer

Dec 5th, 2017 - Newly released results from the MONALEESA-7 trial showed that adding ribociclib to standard endocrine therapy with temporary ovarian suppression significantly improved progression-free survival as a first-line treatment for pre- and perimenopausal women with advanced HR-positive/HER2-negative breast cancer.

Abstract P5-22-22: Breast tumor location in BRCA mutation carriers and implications for prevention
http://cancerres.aacrjournals.org/content/78/4_Supplement/P5-22-22

Dec 15th, 2018 - Introduction: Close to 65% of BRCA mutation carriers do not choose prophylactic mastectomy, despite their high breast cancer risk. Breast reduction mammoplasty is a surgical technique shown to reduce breast cancer risk and can be modified to target specific areas of the breast. We wondered if a majority of tumors in BRCA mutation carriers would be confined to one quadrant, allowing for the use ...

Abstract P6-11-18: Ten year trends in antiemetic prescribing in cancer patients receiving highly emetogenic chemotherapy (HEC)
http://cancerres.aacrjournals.org/content/78/4_Supplement/P6-11-18

Sep 11th, 2018 - Purpose: Prevention of chemotherapy-induced nausea and vomiting (CINV) is essential to preserve quality of life in cancer patients receiving highly emetogenic chemotherapy (HEC) such as doxorubicin-cyclophosphamide (AC) or cisplatin. Recently, new drugs (e.g. fosaprepitant and newer neurokinin 1 receptor antagonists [NK1RAs], rolapitant and netupitant) and updated guidelines for antiemetic use ...

Abstract P5-22-20: Oncologic safety of endoscopic assisted breast surgery compared with conventional breast surgery: An analysis of 1295 primary operable breast cancer patients from single institute
http://cancerres.aacrjournals.org/content/78/4_Supplement/P5-22-20

Dec 16th, 2018 - Background:Endoscopy-assisted breast surgery (EABS) performed through minimal axillary and/or periareolar incisions is a possible alternative to open surgery for certain patients with breast cancer. In this study, we report the oncologic safety results of EABS compared with conventional breast surgery (CBS). Methods: The medical records of patients who underwent EABS for breast cancer during th...

Statins May Up Breast Cancer-Specific and Overall Survival
http://www.medscape.com/viewarticle/889813

Dec 7th, 2017 - Statins may improve breast cancer outcomes whether women take them before or after their diagnosis and extend overall survival as well.

Abstract P5-22-23: Electrochemotherapy : A new local therapy for cutaneous metastases of breast cancer
http://cancerres.aacrjournals.org/content/78/4_Supplement/P5-22-23

Dec 17th, 2018 - Background : Electrochemotherapy (ECT) is a new local therapy combining the administration of an intravenous chemotherapy (bleomycin) followed by the direct application of electric pulses by an electrode to the treated areas. Electric pulses transiently permeabilize the membrane of the tumor cell ( electroporation), improving intracellular diffusion of a poorly permeant chemotherapeutic agent, ...

Talazoparib improves PFS over chemotherapy for patients with BRCA mutations
https://www.healio.com/hematology-oncology/breast-cancer/news/online/%7Ba100040a-b819-4546-8436-fe6f5a5d16f6%7D/talazoparib-improves-pfs-over-chemotherapy-for-patients-with-brca-mutations

Dec 13th, 2017 - The PARP inhibitor talazoparib improved PFS over investigator’s choice chemotherapy among patients with advanced breast cancer and a BRCA germline mutation, according to results of the phase 3 EMBRACA study presented at the San Antonio Breast Cancer Symposium.

Temporary ovarian suppression preserves fertility during chemotherapy
https://www.healio.com/hematology-oncology/breast-cancer/news/online/%7B275c318a-d8ca-46af-ac78-2c2db173d8ff%7D/temporary-ovarian-suppression-preserves-fertility-during-chemotherapy

Dec 6th, 2017 - Women treated with gonadotropin-releasing hormone agonists during treatment with chemotherapy for premenopausal early breast cancer experienced a significant reduction in the risk for chemotherapy-induced premature ovarian insufficiency, according to data from a systemic review and meta-analysis presented at the San Antonio Breast Cancer Symposium.

Abstract P5-22-04: Efficacy of thoracic paravertebral block for reducing acute post-mastectomy pain
http://cancerres.aacrjournals.org/content/78/4_Supplement/P5-22-04

Dec 18th, 2018 - Background: Mastectomy is associated with acute and chronic postoperative pain. This study investigated the efficacy of thoracic paravertebral block (TPB) compared to local anesthetic of surgical wound (LASW) in breast cancer patients undergoing mastectomy. Methods: This phase 3, randomized controlled, single blind, parallel arms and superiority clinical trial aimed to evaluate the efficacy of ...

Trastuzumab Deruxtecan Impresses in HER2 Expressing Breast Cancers
https://www.onclive.com/conference-coverage/sabcs-2017/trastuzumab-deruxtecan-impresses-in-her2-expressing-breast-cancers

Dec 7th, 2017 - Trastuzumab deruxtecan (ds-8201a), a HER2-targeting antibody-drug conjugate, demonstrated significant clinical activity in heavily pretreated patients with HER2-expressing metastatic breast cancers.

Trastuzumab Disappoints in HER2-low Patient Cohort
https://www.onclive.com/conference-coverage/sabcs-2017/trastuzumab-disappoints-in-her2low-patient-cohort

Dec 5th, 2017 - A trial to determine the value of trastuzumab plus standard adjuvant chemotherapy in patients with low levels of HER2 protein has shown no significant efficacy, confounding investigators who launched the trial based on opposing results from 2 earlier studies.

Abstract P6-13-04: IMPACt trial: MammaPrint and BluePrint molecular subtyping guide treatment decisions in breast cancer
http://cancerres.aacrjournals.org/content/78/4_Supplement/P6-13-04

Sep 15th, 2018 - Background: IMPACt is a prospective, case-only study to measure the effect of MammaPrint (MP) and BluePrint (BP) on treatment decisions in breast cancer patients. Here, we report the results of the primary objective in women aged ≥18 years with histologically proven invasive stage I-II, hormone receptor (HR) positive, and HER2-negative breast cancer. Methods: The study included 369 women from 1...

Abstract P5-22-10: Intraoperative ultrasound guided surgery after neoadjuvant treatment in breast cancer improves patient´s quality of life
http://cancerres.aacrjournals.org/content/78/4_Supplement/P5-22-10

Dec 20th, 2018 - Background: Intraoperative ultrasound guided surgery (IOUS) has shown not only to improve surgical outcomes by achieving higher rates of negative margins and reducing the need for re-excisions, but also showing better cosmetic results and patient's satisfaction in the adjuvant setting. After neoadjuvant treatments (NAT) we have shown that IOUS lowers the volume of resection in patients with pat...

Wider margins may reduce recurrence risk in early breast cancer
https://www.mdedge.com/oncologypractice/article/155336/breast-cancer/wider-margins-may-reduce-recurrence-risk-early-breast

Jan 1st, 2018 - A margin width beyond ‘no tumor on ink’ may reduce local recurrence in certain subsets of patients undergoing breast-conserving treatment for early-stage breast cancer, according to findings from a meta-analysis.

Abstract P6-13-03: Breast cancer-specific mortality (BCSM) in patients with node-positive (N+) breast cancer (BC) treated based on the 21-gene assay in clinical practice
http://cancerres.aacrjournals.org/content/78/4_Supplement/P6-13-03

Sep 17th, 2018 - Introduction: The Recurrence Score® (RS) assay was shown in SWOG 8814 to predict chemotherapy (CT) benefit for patients (pts) with N+ BC and RS ≥31 but not RS <18. As we await the randomized RxPONDER results for RS 0-25, we characterized BCSM for RS groups (cutoffs of 11, 18, 25, and 31) in the large population-based SEER study of pts treated based on RS results. Methods: RS results were provid...

Abstract P5-22-19: Nipple sparing mastectomy in unselect patients: Experience of an academic center in the south of Brazil
http://cancerres.aacrjournals.org/content/78/4_Supplement/P5-22-19

Dec 21st, 2018 - INTRODUCTION: Nipple sparing mastectomy (NSM) consists in the complete excision of the breast gland, mantaining the subcutaneous tissue, skin and nipple-areola complex (NAC). Recently, the NSM was developed as a therapeutic option not just for the patients that need risk-reducing surgery, but also for patients that have tumors not involving the NAC. OBJECTIVES: Evaluate the overall survival, di...

Abstract P1-01-01: The blood-Tumor barrier as a therapeutic target to improve therapy of brain metastases of breast cancer
http://cancerres.aacrjournals.org/content/78/4_Supplement/P1-01-01

Feb 14th, 2018 - Objectives: Brain metastases of breast cancer demonstrate low and heterogeneous levels of permeability to drugs in mouse models and human craniotomies. The Blood-Brain Barrier (BBB), the protective lining of CNS blood vessels, impedes drug entry into the normal brain. When a metastasis forms, the BBB is locally altered to a poorly characterized Blood-Tumor Barrier (BTB). Quantitative experiment...

Abstract P1-15-03: Management and outcomes of metaplastic breast cancer
http://cancerres.aacrjournals.org/content/78/4_Supplement/P1-15-03

Sep 21st, 2018 - Purpose/Objectives: Metaplastic breast cancer (MBC) is a rare malignancy composed of both epithelial and mesenchymal components that accounts for less than 1% of primary breast carcinomas. Knowledge of effective management of the disease remains limited. We retrospectively evaluated the treatment and outcomes of patients with MBC from three academic hospitals. Materials/Methods: Patients diagno...

Abstract GS5-04: Prediction of occult invasive disease in ductal carcinoma in situ using deep learning features
http://cancerres.aacrjournals.org/content/78/4_Supplement/GS5-04

Feb 27th, 2018 - Background: Deep learning, especially deep convolutional neural network (CNN), has emerged as a promising approach for many image recognition or classification tasks, demonstrating human or even superhuman performance. Used as feature extractor, some pre-trained CNN models can match or surpass the performance of domain-specific, “handcrafted” features. In this study, we aim to determine whether...

Abstract P5-22-12: Oncological safety of nipple-areola sparing mastectomy in comparison with skin sparing and total mastectomy: Results from a NCI-designated comprehensive cancer center
http://cancerres.aacrjournals.org/content/78/4_Supplement/P5-22-12

Dec 26th, 2018 - Nipple-areola sparing mastectomy (NSM) may be offered to some women with breast cancer as an alternative to skin sparing (SSM) or total mastectomy (TM) with excellent cosmetic results and acceptable recurrence risk. The aim of this study is to determine the local/regional recurrence rate of NSM in comparison to SSM and TM at our institution and to determine the factors that may be associated wi...

Abstract GS3-02: Invasive disease-free survival and gene expression signatures in CALGB (Alliance) 40601, a randomized phase III neoadjuvant trial of dual HER2-targeting with lapatinib added to che...
http://cancerres.aacrjournals.org/content/78/4_Supplement/GS3-02

Mar 7th, 2018 - Purpose Dual HER2 targeting increases pathologic complete response (pCR) rate to neoadjuvant therapy and improves outcomes in both early and metastatic HER2-positive disease. CALGB 40601 is a randomized phase III trial examining the impact of dual HER2 blockade consisting of trastuzumab (H) and lapatinib (L) added to paclitaxel (T) on pCR, considering tumor and microenvironment molecular featur...

Abstract P3-14-03: PRESAGE : Prospective multicenter feasibility study of fertility preservation before neoadjuvant or adjuvant chemotherapy for breast cancer: Preliminary results
http://cancerres.aacrjournals.org/content/78/4_Supplement/P3-14-03

Dec 28th, 2018 - Background: Breast cancer is the most frequent form of cancer for young women. For these patients, breast cancer is generally more aggressive and chemotherapy is more often needed. Chemotherapy is commonly associated with amenorrhea and a decrease of ovarian reserve depending on the patient's age, agents and dose. There are no guidelines to prevent subfertility for young women on cytotoxic trea...

Abstract GS1-04: Copy number aberration analysis to predict response to neoadjuvant anti-HER2 therapy: Results from the NeoALTTO phase III trial
http://cancerres.aacrjournals.org/content/78/4_Supplement/GS1-04

Mar 6th, 2018 - Background In the NeoALTTO trial, the combination of trastuzumab and lapatinib for the neoadjuvant treatment of HER2 positive early breast cancer patients (pts) nearly doubled the rate of pathological complete response (pCR) compared with either anti-HER2 treatment alone. In the same trial, pCR was shown to be a surrogate for long-term outcome. Expression of ERBB2, ESR1 and immune signatures we...

Abstract P3-14-02: Incidence of venous thromboembolism in patients with hormone receptor-positive HER2-negative metastatic breast cancer treated with CDK 4/6 inhibitors: A systematic review and met...
http://cancerres.aacrjournals.org/content/78/4_Supplement/P3-14-02

Dec 29th, 2018 - Background: The cyclin dependent kinases (CDK) along with their partners, the cyclins, have a crucial role in regulation of the cell cycle. Several CDK-targeted agents have been employed in hormone receptor positive metastatic breast cancer (MBC) with noteworthy safety concerns. Nevertheless, the impact of this agent on risk of venous thromboembolism (VTE) remains uncertain. We performed a syst...

Abstract GS3-08: Pathological complete response predicts event-free and distant disease-free survival in the I-SPY2 TRIAL
http://cancerres.aacrjournals.org/content/78/4_Supplement/GS3-08

Mar 10th, 2018 - Background: Pathological complete response (pCR) is accepted by FDA as a surrogate endpoint for accelerated approval of targeted agents in combination with chemotherapy based on better long-term outcomes compared to residual disease (Cortazar 2014). Methods: The multi-center, adaptively-randomized I-SPY2 platform trial uses pCR as the primary endpoint to identify investigational agents that wil...

Abstract P3-14-09: Low rates of chronic breast cancer related lymphedema (BCRL) in a cohort of high-Risk patients undergoing prospective surveillance with bioimpedance spectroscopy (BIS)
http://cancerres.aacrjournals.org/content/78/4_Supplement/P3-14-09

Dec 30th, 2018 - Background: We report outcomes using prospective BIS surveillance in a high-risk cohort of patients who all underwent axillary lymph node dissection (ALND). Methods: From 8/2010 through 12/2016, 206 consecutive patients were evaluated with BIS as part of a prospective surveillance program. 30 underwent ALND and constitute the study population. The program included pre-operative BIS measurement ...

Abstract GS6-04: The EndoPredict score predicts residual cancer burden after neoadjuvant chemotherapy and after neoendocrince therapy in HR+/HER2- breast cancer patients from ABCSG 34
http://cancerres.aacrjournals.org/content/78/4_Supplement/GS6-04

Mar 14th, 2018 - Background: In the neoadjuvant treatment setting of ER+/HER2- breast cancer (BC) the choice between preoperative endocrine - (NET) or preoperative chemotherapy (NCT) is largely based on the expression of hormone receptors (HR), grading and possibly Ki-67. The EndoPredict 12-gene molecular score (EP) is a validated prognostic score based on the expression of genes involved in cellular processes ...

Abstract P1-14-03: ABRAZO: Exposure-efficacy and -safety analyses of breast cancer patients with germline BRCA1/2 mutations receiving talazoparib in a phase 2 open-label trial
http://cancerres.aacrjournals.org/content/78/4_Supplement/P1-14-03

Sep 27th, 2018 - Background: Talazoparib (TALA) is a dual-mechanism poly (ADP-ribose) polymerase (PARP) inhibitor that traps PARP on DNA. Efficacy results of this phase 2 trial were previously presented (Turner et al, ASCO 2017, abstract 1007). This study included sparse pharmacokinetic (PK) sampling for patients through cycle 4 of therapy. Exploratory analyses included assessment of exposure versus parameters ...

Abstract GS4-04: Randomized blinded sham- and waitlist-controlled trial of acupuncture for joint symptoms related to aromatase inhibitors in women with early stage breast cancer (S1200)
http://cancerres.aacrjournals.org/content/78/4_Supplement/GS4-04

Mar 18th, 2018 - Background: Musculoskeletal symptoms are the most common side effect of aromatase inhibitors (AIs) and can result in decreased quality of life and discontinuation of therapy. Pilot data from two prior single institution studies showed that acupuncture decreased AI-induced joint symptoms in breast cancer (BC) patients. Methods: We conducted a SWOG multicenter randomized controlled trial among po...

Abstract P1-14-05: Ribociclib dose recommendations for potential pharmacokinetic drug interaction and in special patient populations with organ impairment
http://cancerres.aacrjournals.org/content/78/4_Supplement/P1-14-05

Sep 28th, 2018 - Background: Ribociclib (Kisqali®) is a CDK4/6 inhibitor, recently approved in the U.S. as a first line therapy for HR+/HER2- advanced breast cancer (ABC) in combination with an aromatase inhibitor. The recommended starting dose is 600 mg/day orally (3 wks-on/1 wk-off). Ribociclib inhibits CYP3A4 and its metabolism is mostly CYP3A4-mediated. Here we evaluate the effect of food, conmeds and speci...

Abstract CS1-2: Searching for the optimal duration of adjuvant endocrine therapy in breast cancer
http://cancerres.aacrjournals.org/content/78/4_Supplement/CS1-2

Mar 27th, 2018 - Endocrine therapy is an integral part of the adjuvant systemic management of women with early stage hormone receptor-positive breast cancer. Adjuvant endocrine therpay is associated with significant improvements in disease-free and overall survival. Several adjuvant endocrine therapy approaches are available to women based on their menopausal status, disease stage, tumor characteristics, co-mor...

Abstract P3-14-01: Effects of adding budesonide or colestipol to loperamide prophylaxis on neratinib-associated diarrhea in patients with HER2+ early-stage breast cancer: The CONTROL trial
http://cancerres.aacrjournals.org/content/78/4_Supplement/P3-14-01

Jan 1st, 2019 - Background: Neratinib is an irreversible pan-HER tyrosine kinase inhibitor. Results from the randomized, placebo-controlled, Phase III ExteNET study demonstrated that neratinib significantly improves 24-month iDFS in patients (pts) with trastuzumab-treated early-stage HER2+ breast cancer (HR 0.67; 95% CI 0.50–0.91; p=0.009) [Chan et al. Lancet Oncol 2016]. In ExteNET, loperamide prophylaxis was...

Abstract P1-14-04: Overall survival in metastatic breast cancer patients in the third millennium: Results of an Italian study
http://cancerres.aacrjournals.org/content/78/4_Supplement/P1-14-04

Oct 1st, 2018 - BACKGROUND - Metastatic breast cancer (MBC) is a life-threatening disease. It is important to provide data about real-life MBC patients (pts) to understand the current prognostic factors. The aim of the present observational study, named COSMO (Checking Overall Survival in a MBC Observational study) is to describe the overall survival (OS) in a large cohort of MBC pts, assessing its correlation...

Abstract P3-14-10: Proposed biosimilar pegfilgrastim LA-EP2006 shows similarity in pharmacokinetics and pharmacodynamics to reference pegfilgrastim in healthy subjects
http://cancerres.aacrjournals.org/content/78/4_Supplement/P3-14-10

Jan 3rd, 2019 - Background: Granulocyte colony-stimulating factors such as filgrastim and its long-acting version pegfilgrastim are widely used to prevent neutropenia in patients receiving chemotherapy. LA-EP2006 is a proposed biosimilar pegfilgrastim that has been compared with reference pegfilgrastim and shown to have no clinically meaningful differences regarding efficacy and safety in breast cancer patient...

Abstract ES2-3: Managing increased breast cancer risk based on high and moderate penetrance gene mutations
http://cancerres.aacrjournals.org/content/78/4_Supplement/ES2-3

Apr 7th, 2018 - Genetic testing in the modern era increasingly examines multiple genes using next generation technologies. Most assays include the high penetrance genes, which confer lifetime breast cancer risk greater than 5-fold, include BRCA1/2, TP53, CDH1 and PALB2. Moderate penetrance genes are associated with lifetime breast cancer risk in the range of 2-3 fold, and include ATM, NF1, CHEK2 (mutation-spec...

Abstract ES7-1: Challenges in the management of locoregional recurrence
http://cancerres.aacrjournals.org/content/78/4_Supplement/ES7-1

Apr 16th, 2018 - The increasing trend toward tailoring treatment of the primary breast cancer with limited surgery of both the breast and axilla has increased the challenge of managing locoregional recurrence (LRR). In the era when patients uniformly had axillary dissection, the appropriateness of repeat sentinel node biopsy was not a question. Similarly, the dogma that all ipsilateral breast tumor recurrences ...

Abstract ES8-2: Exosome analysis in breast cancer: Clinical translation
http://cancerres.aacrjournals.org/content/78/4_Supplement/ES8-2

Apr 11th, 2018 - There is a growing appreciation that tumor secreted factors can function by orchestrating the cross-talk between cancer, stromal and immune cells. Tumors constitutively release membrane-derived extracellular vesicles (EVs) or exosomes that are readily detected in body fluids and have been appreciated to play important roles in signaling, immunomodulation and metastasis. We examined the role of ...

Abstract ES4-3: Can we improve treatment tailoring in advanced HER2+ breast cancer?
http://cancerres.aacrjournals.org/content/78/4_Supplement/ES4-3

Apr 20th, 2018 - In the 1980s the importance of HER2 signalling to the aberrant behaviour of certain breast cancer cells was recognized for the first time. The intervening 3 decades have seen an immense international translational and clinical research effort that at first identified a hitherto unknown subtype of breast cancer – HER2-positive breast cancer - and then went on to entirely transform the natural hi...

Abstract ES10-1: Genetic dissection of cancer development, therapy response, and resistance in mouse models of breast cancer
http://cancerres.aacrjournals.org/content/78/4_Supplement/ES10-1

Apr 15th, 2018 - Genetically engineered mouse models (GEMMs) and patient-derived xenograft (PDX) models of breast cancer have proven invaluable for basic and translational cancer research. These preclinical models have been useful for in vivo analysis of breast cancer initiation and progression, as well as for investigating anti-tumor efficacy of targeted drugs and immunotherapeutics. However, the establishment...

Abstract ES4-2: Adjuvant therapy for HER2-positive breast cancers: is less more?
http://cancerres.aacrjournals.org/content/78/4_Supplement/ES4-2

Apr 19th, 2018 - The use of trastuzumab-based chemotherapy has dramatically improved outcome for patients with early stage HER2-positive breast cancer. Given the excellent outcomes seen to date and the toxicities associated with therapy, it is critical to establish whether additional therapies can further improve outcome, and conversely if there are patients who would have a favorable outcome with less therapy....

Abstract P1-17-01: Development of brain metastases in breast cancer patients treated in the neoadjuvant trials Geparquinto and Geparsixto
http://cancerres.aacrjournals.org/content/78/4_Supplement/P1-17-01

Oct 5th, 2018 - Background: The incidence of brain metastases (BM) in breast cancer patients is rising and has become a major clinical challenge. So far, the incidence of BM after modern neoadjuvant treatment is not clear. Materials and Methods: In Geparquinto, patients with untreated HER2-positive breast cancer (n=615) received either lapatinib or trastuzumab, patients with HER2 negative breast cancer (n=1925...

Abstract MS2-2: Understanding the unique biology of ILC
http://cancerres.aacrjournals.org/content/78/4_Supplement/MS2-2

Apr 28th, 2018 - Invasive lobular breast cancer (ILC) is characterized by distinct etiological, pathological, and clinical features, yet the underlying biology is poorly understood. To extend the molecular determinants of ILC beyond the well-known loss of E-cadherin, we combined a plethora of in silico and wet-bench approaches, and comprehensively characterized ILC tumor models and clinical samples. In support ...

Abstract MS2-3: Tailoring systemic therapy for patients with lobular breast cancer
http://cancerres.aacrjournals.org/content/78/4_Supplement/MS2-3

Apr 27th, 2018 - Recent developments in breast cancer treatment include an increasing awareness of the role of systemic therapies in selected subgroups of patients. A consequence of this strategy is the importance of accurate and reliable histopathological assessment. Through the identification of lobular breast cancer, that account for up to 15% of all invasive breast carcinomas, it is possible to select patie...

Abstract P1-17-10: Survival outcomes related to health care coverage in breast cancer patients with brain metastases in Brazil: A sub-analysis from the LACOG-0312 study
http://cancerres.aacrjournals.org/content/78/4_Supplement/P1-17-10

Oct 7th, 2018 - Background The incidence of brain metastases among women with metastatic breast cancer (MBC) ranges from 10 to 30% depending of breast cancer (BC) subtype. Inequities in the access to optimal treatment and shorter survival of BC by type of health care coverage were previously reported in an observational study in Brazil. The present analysis aims to analyze the impact of the type of health care...

Abstract P3-14-07: Early detection of chemotherapy-induced cardiotoxicity in breast cancer patients
http://cancerres.aacrjournals.org/content/78/4_Supplement/P3-14-07

Jan 7th, 2019 - BACKGROUND The incidence of cardiotoxicity in patients receiving treatment for breast cancer is unknown. There is not enough evidence about early detection and appropriate management of cardiotoxicity. The aim of this study is to identify early markers of risk of cardiac toxicity. MATERIAL AND METHOD Prospective study was conducted between 2014 and 2017 based on a cohort of 97 patients diagnose...

Abstract P5-09-02: Tβ4 expression in cancer-associated endothelial cells enhances progression of invasive breast cancer
http://cancerres.aacrjournals.org/content/78/4_Supplement/P5-09-02

Jan 8th, 2019 - Background: Invasive breast cancer is a highly aggressive primary breast tumour with poor prognosis. As tumour angiogenesis is exhibited by invasive breast cancer, anti-angiogenic therapy has been intensively evaluated over the past decade. However, clinical studies were disappointing. Thymosin β4 (Tβ4), a multi-functional peptide, is associated with induction of angiogenesis, but the role of T...

Abstract P2-01-10: Circulating CAF/CTC complexes and breast cancer metastasis
http://cancerres.aacrjournals.org/content/78/4_Supplement/P2-01-10

May 10th, 2018 - Background: Metastatic disease in breast cancer (BC) is the leading cause of cancer-related mortality among women worldwide. Synergy between cancer cells and non-cancer cells of the tumor microenvironment (TME) are vital for disease progression. Cancer associated fibroblasts (CAFs) are the major cell type in the stroma of BC and are critical mediators of tumor progression and metastasis. Transp...

Abstract P1-17-02: Ado-trastuzumab emtansine (TDM-1) treatment and brain metastases in HER2 positive metastatic breast cancer patients: Final analysis of an italian multicenter study
http://cancerres.aacrjournals.org/content/78/4_Supplement/P1-17-02

Oct 9th, 2018 - Background: Ado-trastuzumab emtansine (T-DM1) is a drug-antibody conjugate whose activity has been confirmed in HER2+ advanced breast cancer (BC) patients by the phase 3 EMILIA trial (Verma et al, NEJM 2012). Within the 991 patients enrolled in this trial, about 10% were affected with brain metastases (BM); in this subgroup, safety and efficacy of T-DM1 were confirmed although without any PFS i...

Abstract P1-17-03: Abemaciclib for the treatment of brain metastases secondary to hormone receptor positive breast cancer
http://cancerres.aacrjournals.org/content/78/4_Supplement/P1-17-03

Oct 11th, 2018 - Background: Although a lower percentage of patients with hormone receptor-positive (HR+) metastatic breast cancer (MBC) develop brain metastases when compared with triple negative and HER2+ MBC patients, there are no regulatory approved systemic agents for the treatment of HR+ breast cancer brain metasteses, and this remains an unmet medical need. Standard local treatment options include surger...

Abstract P1-17-08: Efficacy of lapatinib and capecitabine combination therapy in brain metastases from HER-2 positive metastatic breast cancer: A systematic review and meta- analysis
http://cancerres.aacrjournals.org/content/78/4_Supplement/P1-17-08

Oct 12th, 2018 - Background: Brain metastases contribute to significant morbidity and mortality in breast cancer. Approximately one fourth of breast tumors overexpress the human epidermal growth factor receptor 2 (HER2) protein and are twice as likely to develop brain metastases. There are currently no systemic therapies approved. We undertook a systematic review and pooled analysis of trials to determine the e...

Abstract P6-03-04: Central nervous system miliary metastasis in breast cancer patients
http://cancerres.aacrjournals.org/content/78/4_Supplement/P6-03-04

May 22nd, 2018 - Background: Little is known regarding central nervous system (CNS) miliary metastasis (MiM), which was first described as “carcinomatous encephalitis” by Madow and Alpers in 1951. The majority of reported cases arise from primary lung and gastrointestinal adenocarcinomas, with occasional melanoma primaries and one reported case in breast cancer. Moreover, clinicopathologic correlates, disease o...

Abstract P6-04-02: CDK6 might be a key factor for efficacy of CDK4/6 inhibitor and the hormone sensitivity following acquired resistance
http://cancerres.aacrjournals.org/content/78/4_Supplement/P6-04-02

Jan 12th, 2019 - Background: CDK4/6 inhibitors have received FDA breakthrough therapy designation as 1st line treatment for advanced estrogen receptor positive breast cancer patients. However, the benefit offered by CDK4/6 inhibitors is individually different and furthermore acquired resistance to the drugs is monumental challenges. It is urgent need to search for the biomarker and understand the drug sensitivi...

Abstract P6-03-06: Assessing occult brain metastasis with CT scan or MRI in HER2-positive breast cancer patients at initial diagnosis
http://cancerres.aacrjournals.org/content/78/4_Supplement/P6-03-06

May 26th, 2018 - Patients (pts) with HER2-positive breast cancer (BC) have a high risk of developing brain metastases (BM) that might be due to longer survival, low diffusion of Trastuzumab (T) in the CNS or an unknown incidence of occult BM at diagnosis. In a series of metastatic BC, occult metastasis was found in 15 % of the patients and Her2 over expression was an independent risk factor 1.In a series of ear...

Abstract P6-04-01: Rapalog everolimus induces G1 cell cycle arrest through autophagy-mediated protein degradation of cyclin D1 in breast cancer cells
http://cancerres.aacrjournals.org/content/78/4_Supplement/P6-04-01

Jan 13th, 2019 - Rapamycin analogs (rapalogs) inhibit mammalian target of rapamycin (mTOR) and are known to cause induction of autophagy and G1 cell cycle arrest. However, it remains unknown whether rapalog-induced autophagy plays a critical role in its regulation of cell cycle. We, for the first time, found that rapalog everolimus could stimulate autophagy-mediated Cyclin D1 degradation in breast cancer cells....

Abstract P6-10-06: Racial differences in the characteristics and outcomes of young breast cancer patients: A national population-based study
http://cancerres.aacrjournals.org/content/78/4_Supplement/P6-10-06

Jun 2nd, 2018 - Background: Disparity in demographic characteristics as it relates to breast cancer outcomes is well-studied. However, studies evaluating racial differences exclusively among young patients are more limited. We sought to examine socioeconomic and clinical factors and their impact on outcomes in young patients, as well as to determine whether variation in outcomes changed over the 22-year study ...

Abstract P6-05-04: mRNA expression of PTK6V1 and PTKV2 in human breast cancer
http://cancerres.aacrjournals.org/content/78/4_Supplement/P6-05-04

Jan 14th, 2019 - BACKGROUND: Protein tyrosine kinase 6 (PTK6) is an intracellular protein that is upregulated in several human cancers and its localization to the plasma-membrane facilitates its various oncogenic roles in breast cancer cell proliferation, survival, and migration. The full length protein (PTK6V1) and alternative splice variant (PTK6V2) seem to play different roles with the latter being negative ...

Abstract P6-10-03: The association between type-2 diabetes and risk of mortality after invasive breast cancer among Hispanic and non-Hispanic white women from New Mexico
http://cancerres.aacrjournals.org/content/78/4_Supplement/P6-10-03

Jun 3rd, 2018 - Background: Evidence suggests that the presence of Type-2 diabetes at the time of breast cancer diagnosis adversely affects survival independent of breast cancer stage, grade, and tumor phenotype. Few of these epidemiological studies have included Hispanic breast cancer survivors in whom diabetes and obesity are prevalent. Objective: We examined the association between self-reported diabetes hi...

Abstract P3-17-01: Geographic variation in adverse event reporting patterns in breast cancer clinical trials
http://cancerres.aacrjournals.org/content/78/4_Supplement/P3-17-01

Oct 16th, 2018 - Introduction: Adverse event (AE) reporting in clinical trials (CT) informs the safety of investigational products. Once approved, safety information in the monograph and prescribing information mainly derive from CT data. Some studies have shown geographic variations in the AE reporting patterns in multinational CT; none of them assessed this variation in cancer CT. We conducted a study to anal...

Abstract P4-06-08: An interlaboratory study of complex mutation detection in genes associated with hereditary breast and ovarian cancer highlights both successes and current challenges
http://cancerres.aacrjournals.org/content/78/4_Supplement/P4-06-08

Jun 10th, 2018 - Background: Established laboratory methods, including next-generation sequencing (NGS), can accurately and inexpensively detect certain classes of clinically important mutations in readily accessible protein coding regions of a patient's DNA. These events include single nucleotide variants (SNVs), small insertions/deletions (indels), and sometimes medium sized copy-number deletions or duplicati...

Abstract P1-08-05: A phase I trial of chemotherapy followed by infusions of activated T cells armed with anti-CD3 and anti-HER2 bispecific antibody for stage III, Her2+ or Her2- breast cancer
http://cancerres.aacrjournals.org/content/78/4_Supplement/P1-08-05

Oct 17th, 2018 - Background: The balance in the immune system between immune surveillance and tolerance is known to be associated with the prognosis of breast cancer patients. The aim of this phase I study was to assess the safety of anti-CD3 x anti-HER2Bi bispecific antibody targeted (BAT) activated T cells (TC) in high risk breast cancer patients. The BAT T-cells exhibit anti-HER2 cytotoxicity, proliferate, a...

Abstract P4-06-11: Is myriad a reliable genetic risk model for prediction BRCA1/2 mutations in Romanian high-risk breast cancer patients?
http://cancerres.aacrjournals.org/content/78/4_Supplement/P4-06-11

Jun 15th, 2018 - Aim: To assess the predictive efficacies of genetic risk model Myriad for BRCA1/2 mutations in high-risk Romanian breast cancer patients (pts). Methods: This prospective study evaluated the validity of Myriad risk assessment model for 250 high-risk breast cancer pts tested for BRCA1/2 mutations between 02.2015-12.2016 at IOCN. Inclusion criteria selected pts diagnosed with triple negative breas...

Abstract P3-09-09: Assessing utility of breast cancer risk assessment tool in comparison to Tyrer-Cuzick model for determination of breast cancer risk and implications for chemoprevention
http://cancerres.aacrjournals.org/content/78/4_Supplement/P3-09-09

Jun 22nd, 2018 - Background Despite findings that the Tyrer-Cuzick (IBIS Breast Cancer Risk Evaluation Tool or TC) model is more predictive of breast cancer risk than the Gail model (NCI maintained Breast Cancer Risk Assessment Tool or BCRAT), BCRAT is commonly clinically used as per the United States Preventive Services Task Force (USPSTF), with a 5-year risk for breast cancer (BC) of greater than 3% on BCRAT,...

Abstract P4-14-01: Changes in treatment and improved survival of inflammatory breast cancer (IBC/T4d) and T4a-c lesions: 1990-2014
http://cancerres.aacrjournals.org/content/78/4_Supplement/P4-14-01

Oct 20th, 2018 - Background: T4 breast cancer (BC) is a tumor of any size with direct extension to the chest wall and/or to the skin. Tumor stage T4a-d including IBC (T4d) are aggressive cancers, often presenting with distant metastases or progressing quickly to metastatic breast cancer (MBC). Methods: We conducted a retrospective cohort analysis of invasive BC cases with T4 tumor stage from a prospectively col...

Abstract P3-09-06: Predicting cardiovascular versus cancer mortality in a cohort of breast cancer survivors
http://cancerres.aacrjournals.org/content/78/4_Supplement/P3-09-06

Jun 23rd, 2018 - Background: Given improved survival after breast cancer diagnosis for women with non-metastatic disease, many will likely survive their disease and ultimately die from causes other than breast cancer, the most frequent being cardiovascular disease. There are numerous risk prediction models, such as the Framingham risk score, to identify persons who are at high risk for a cardiovascular event or...

Abstract P4-14-02: CSF1/CSF1R axis reprograms epithelial-to-mesenchymal phenotypes in inflammatory breast cancer
http://cancerres.aacrjournals.org/content/78/4_Supplement/P4-14-02

Oct 21st, 2018 - Inflammatory breast cancer (IBC) accounts for 2% of breast cancers but 10% of breast cancer-related deaths in the US. Clinical hallmarks of IBC are tumor cell emboli in lymphatic vessels and overexpression of E-cadherin, which promotes cell clustering. Given these hallmarks, IBC is thought to spread via collective invasion and cell clusters. However, we showed that IBC cells underwent epithelia...

Abstract P3-09-08: Overeating and breast cancer risk by pathologic subtypes: EpiGEICAM study
http://cancerres.aacrjournals.org/content/78/4_Supplement/P3-09-08

Jun 27th, 2018 - Introduction: It has been reported that overeating may be the greatest avoidable cause of cancer in nonsmokers and obesity increases postmenopausal breast cancer (BC) risk. Calorie restriction reduces BC incidence in experimental animals, but the evidence in humans is more limited. This study analyzes the association between female BC risk and excessive or restricted calorie consumption in Spai...